The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials.

Josep Franch-NadalSamuel Joseph Paul MalkinBarnaby HuntVirginia MartínMaría Gallego EstébanezJosep Vidal

Published in: Advances in therapy (2022)

Oral semaglutide 14 mg was dominant versus sitagliptin and liraglutide, and cost-effective versus empagliflozin, for the treatment of type 2 diabetes in Spain.

Keyphrases

clinical trial
healthcare
public health
mental health
randomized controlled trial
open label